CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Celldex Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contracts and grants | $111.00K | $819.00K | $1.45M | $2.54M | $5.72M | $7.50M | $7.01M | $9.71M | $8.04M | $5.79M | $6.61M | $4.32M | 70.3% | -98.1% |
| Product development and licensing agreements | – | – | $97.00K | $65.00K | $68.00K | $61.00K | $13.00K | $264.00K | $263.00K | $279.00K | $278.00K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Celldex Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.